Thus, a CDK9 inhibitor in combination with the AKT inhibitor, LY294002, or the proteasome inhibitor, MG-132, may provide a potentially therapeutic strategy to enhance the sensitivity of breast cancer cells to CDK9 inhibition. Here, AKT1 is linked to breast carcinoma.